Tag - 6IRA

Developments

USPTO issues NOA for IRLAB’s Parkinson’s drug candidate

IRLAB Therapeutics (STO: IRLAB-A; FRA: 6IRA) has announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent application covering IRL1117, a preclinical drug candidate...

October 27, 2026

Developments

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that the European Medicines Agency (EMA) has granted a waiver allowing the company to bypass pediatric studies of mesdopetam, enabling a focus on patient groups...

January 23, 2025

Developments

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that it has enrolled the last patient in its ongoing Phase IIb study of Pirepemat for Parkingson’s disease. The company also reports that a reduction in falls has...

September 30, 2024

Tag - 6IRA

USPTO issues NOA for IRLAB’s Parkinson’s drug candidate

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

Subscribe